Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03059446 · ClinicalTrials.gov registry record · Phase 2
Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis
A Phase 2 study, sponsored by Tobira Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT03059446 is a Phase 2 study that was terminated before completion, run by Tobira Therapeutics. The registered enrollment target is 167 participants.
The verdict
NCT03059446, a Phase 2 study, was terminated before completion, sponsored by Tobira Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
This rollover study will provide open-label treatment with cenicriviroc and will assess the long-term safety of continued treatment with cenicriviroc in participants who participated in either the CENTAUR study 652-2-203 \[NCT02217475\] or the AURORA study \[NCT03028740\].
Interventions
- DRUG Cenicriviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2017-02-14 |
| Est. Completion | 2021-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03059446
The ClinicalTrials.gov registry entry for NCT03059446 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tobira Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cenicriviroc is the first listed.
NCT03059446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03059446 about?
NCT03059446 is a clinical study titled "Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis". This rollover study will provide open-label treatment with cenicriviroc and will assess the long-term safety of continued treatment with cenicriviroc in participants who participated in either the CENTAUR study 652-2-203 \[NCT02217475\] or the AURORA study \[NCT03028740\].
What is the current status of trial NCT03059446?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2017-02-14. Estimated completion is 2021-01-05.
What interventions are being tested in trial NCT03059446?
The interventions under investigation include: Cenicriviroc (DRUG).
Who is sponsoring clinical trial NCT03059446?
This trial is sponsored by Tobira Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.